Skip To Main Content
Ying Yuan on Muck Rack

Ying Yuan

Houston
As seen in: Color Research & Application, Nature, Wiley Online Library, arXiv, Journal of Empirical Finance, Memory Studies, PLOS ONE, BMJ Oncology, Elsevier, Eyes on Earth and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy of everolimus and letrozole with or without ribociclib in recurrent endometrial cancer: a phase 2 randomized clinical trial

|
By Jeffrey A. How, Shannon N. Westin, Melissa Pham, Barrett Craig Lawson, Minxing Chen, Nidhi Tandon, Ying Yuan, Rugang Zhang, Amir A Jazaeri, Anil K Sood, Michaela Onstad Grinsfelder, Kathleen M Schmeler, David Vining, Samantha M. Fix, Yibo Dai, Mikayla B Bowen, Karen H. Lu, Melinda S. Yates, Russell Broaddus, Pamela T. Soliman
| Nature Verified
Abstract In this phase II trial, patients with endometrial cancer (EC) were randomized to everolimus/letrozole with (experimental arm) or without ribociclib (control arm) (ClinicalTrials.gov Identifier: NCT03008408). The primary endpoint was progression-free survival (PFS). Secondary endpoints included toxicity, overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR).
Open in Who Shared Issue with article?

Self-Adapting Priors for Dynamic Borrowing in Three-Arm Non-Inferiority Trials With Pre-Specified Margin

|
By Yuansong Zhao, Ying Yuan, Ram Satya Tiwari
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The open-source R code for all the simulation studies used in this manuscript is available at https://github.com/yuansongz/ASAM. Also, there is a README.md file that describes the contents of the R files and all the source functions. References 1, “Noninferiority Trials,” Trials 1, no. 1 (2000): 19–21, https://doi.org/10.1186/CVM-1-1-019.
Open in Who Shared Issue with article?

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

|
By Yue Liu, Yanqiao Zhang, Rongbo Lin, Xiaobing Chen, Junye Wang, Mudan Yang, Xiujuan Qu, Yunfeng Li, JiaYi Li, Weisheng Zhang, Yong Mao, Ziwei Wang, Zhenyang Liu, Jian Lei, Ye Xu, Yi Jiang, Zhanyu Pan, Liangjun Zhu, Chengcheng Liu, Min Song, Ying Yuan, Kefeng Ding
| Nature Verified
Abstract Bevacizumab plus chemotherapy is the standard first-line therapy for metastatic colorectal cancer (mCRC). To date, no phase 3 trial has compared first-line oral multitargeted TKI versus bevacizumab plus chemotherapy in RAS/BRAF wild-type mCRC. The open-label, noninferiority, randomized, phase 3 trial (ANCHOR; NCT04854668; CTR20210940) evaluated first-line anlotinib versus bevacizumab plus oxaliplatin and capecitabine (CapeOX) in this setting.
Open in Who Shared Issue with article?
See all 181 licensed articles (187 Total)